Blogs, insights, guides and videos on India's unlisted market — all in one place.
<h3>Why are investors who entered the unlisted market in the last 1 year only losing money?</h3> People thought that the unlisted market was a place to buy cheap stocks that could later be sold at higher prices in IPO after the 6-month lock-in period. But in the last 1 year, things have been going the other way. Investors who bought unlisted shares in FY21-22 are losing a lot of money because most IPOs are priced lower than expected or shares in the unlisted market were available at very high valuations. <h4>Few Examples:</h4> <strong>1. Five Star Business-</strong> This unlisted share traded in the unlisted market for between Rs. 200 to Rs. 750 (after split), while the IPO price was Rs. 475 per share. Investors who bought shares above Rs. 500 are already looking at losses from the initial public offering. <strong>2. AGS transact -</strong> This unlisted share traded in the unlisted market for between Rs. 200 to Rs. 550, while the IPO price was Rs.175 per share, and currently, the share is available at Rs.80 per share. Investors who bought shares above Rs. 200 were at loss at the time of the initial public offering. <strong>3. Pharmeasy-</strong> This share was in high demand last year when the market was at boom. The share price was trading above Rs.120 per share. But after a fall in the market, the current market price is Rs.35 per share and the IPO is also delayed for the next 1 or 2 years. <strong>4. Studds -</strong> This unlisted share was in high demand last year and was traded above Rs.2000 per share and currently, the share is available at Rs.950 per share. The share value has already eroded by 50%. <strong>5. HDB -</strong> This unlisted share was in high demand 2 years back i.e. before Covid-19 and was traded above Rs.1200 per share and currently, the share is available at Rs.650 per share. The share value has already eroded by 50%. The aforementioned scripts, together with a large number of other scripts, can be found on the unlisted market, where investors who have invested in the past year have suffered a substantial loss. <h3>Now the question is what is the reason for the same?</h3> The simple rule of making money in the market is to invest in <b>Bear Market </b>i.e. when nobody is buying and selling in <b>Bull Market </b>when everybody is buying. Or Invest in <b>Bull Market </b>and Exit in <b>Bull Market</b>. Don’t wait for <b>Bear Market</b> to sell. In the last 1 year, the investors who bought shares in fancy and high valuations and were unable to exit, are suffering losses. Currently, all the IPOs which are coming are not getting proper responses from the investors and they have to considerably reduce their valuations to complete their IPOs. So, making money is difficult. If you read the unlisted market carefully, during the period around Fy19-20, many unlisted scripts were available at very decent valuations. However, there was hardly any demand for unlisted shares at that time. <h4>For example:</h4> CSK was available at around Rs.50 per share, Fino-Paytech was available at Rs.120 per share, lava was available at Rs.50 per share (<i>adjusting split and bonus</i>), Care Health was available at Rs.80 per share, Nazara tech was available at Rs.300 per share (<i>adjusting bonus</i>), Reliance Retail was available at Rs.800 per share, Tata Tech was available at Rs.1500 per share, Studds was available at Rs.800 per share, etc. The above scripts at that time were available at very good valuations but as demand was less nobody was buying. However, those who invested made a lot of money by selling them in Fy 21-22 when the bull market or demand was at its peak. Below are the prices of some unlisted scripts which peaked in the Fy21-22. <strong>CSK peak price = Rs.250 per share</strong> <strong>Fino-Paytech = Rs.450 per share</strong> <strong>Lava = Rs. 250 per share</strong> <strong>Care Health = Rs.250 per share</strong> <strong>Nazara Tech = Rs.1500 per share</strong> <strong>Reliance Retail = Rs.4000 per share</strong> <strong>Tata Tech = Rs.6000 per share</strong> <strong>Studds = Rs.2000 per share </strong> However, one year ago, investors who purchased at the aforementioned prices are now facing losses. They entered the market when demand was high and the bull market was at its peak. The market then undergoes a severe correction, and many unlisted scripts loose more than 50% of their value, as does the portfolio worth of clients. <h3>Is it the right time to come to an unlisted market to buy again?</h3> Currently, checking the unlisted market reveals that there is no demand coming from investors with brokers in the unlisted market. Investors have no interest in purchasing. In many scripts, prices have already decreased by more than 50%, and additional declines cannot be ruled out. However, still investors are not buying. Those who are well informed and shares where valuation again becomes attractive, those investors have started to accumulate again in smaller lots. UnlistedZone believes that some scripts' valuations are becoming favourable now in the unlisted market and most probably all good scripts' values will become attractive again within the next three to six months. Those that buy now will profit when the bull market returns within the next two to three years.
<p><span style="font-weight: 400;">The National Stock Exchange</span> <span style="font-weight: 400;">of India Limited (NSE) has announced its quarterly consolidated results for the quarter ended September 20, 2022. <br /><br /></span><span style="font-weight: 400;"> </span><span style="font-weight: 400;"> </span><span style="font-weight: 400;">As per the results, the company has registered a 15% growth in its revenue compared to the previous quarter. <br /><br />The total revenue of the company increased to Rs. 3,371 crore from Rs. 2,920 crore in the quarter ended June 30, 2022. </span><span style="font-weight: 400;"> </span><span style="font-weight: 400;"> </span><span style="font-weight: 400;">The total revenue increased by 61% to 3,371 crores from 2082 crores in the same quarter of the previous year. <br /><br />The total expenses of the company have increased 9% to Rs. 823 crore as against Rs. 756 crore in the previous quarter. <br /><br /></span><span style="font-weight: 400;"> </span><span style="font-weight: 400;"> </span><span style="font-weight: 400;">The profit before tax of the company has reported an increase of 18% to Rs. 2,566 crore as against Rs. 2,181 crore in the previous quarter. <br /><br />The net profit of the company widened 5% to Rs. 1,773 crore as against Rs. 1,689 crore in the previous quarter. The net profit increased by 62% to Rs. 1,773 crore as against Rs. 1,095 crore in the same quarter last year. </span> <br /><br /><span style="font-weight: 400;">The total assets of the company increased by 25% to Rs. 44,503 crore as against Rs. 35607 crore in the quarter ended March 31, 2022. <br /><br />The total equity and liabilities of the company increased by 25% to Rs. 44,503 crore as against Rs. 35607 crore in the quarter ended March 31, 2022.</span> <span style="font-weight: 400;">For the half year ended September 30, 2022, the net cash inflow of the company was Rs. 10452 crore as against Rs. 4212 crore in the same period the previous year. <br /><br />The net cash outflow of the company was Rs. 1,224 crore as against Rs. 658 crore in the same period last year. The net cash outflow from financial activities was Rs. 2,182 crore as against Rs. 1,241 crore in the same period last year. <br /><br />The net increase in cash and cash equivalents of the company was Rs. 7,046 crore as against Rs. 2312 crore in the same period last year. </span> <span style="font-weight: 400;">NSE stands for "National Stock Exchange', and was incorporated in 1992 and recognized as a stock exchange in 1993. NSE is the leading stock exchange in India and the second largest in the world by nos. of trades in equity shares from January to June 2018, according to the World Federation of Exchanges (WFE) report. NSE is a pioneer in technology and ensures the reliability and performance of its systems through a culture of innovation and investment in technology and provides valuable data and services to participants and clients. </span></p>
<h3>B9 Beverages Private Limited has announced its annual report for the financial year ended March 31, 2022.</h3> <ul> <li>As per the annual report, in FY22, the gross revenue of the company has reported an increase of 59% to Rs. 733 crore as against Rs. 462 crore in the previous financial year.</li> <li>The total expenses of the company have also increased 59% to Rs. 1069 crore as against Rs. 674 crore in the previous financial year.</li> <li>The Loss Before Tax of the company has also reported an increase of 59% to Rs. 335 crore as against Rs. 211 crore in the previous financial year.</li> <li>The Loss After Tax of the company has also reported an increase of 59% to Rs. 335 crore as against Rs. 211 crore in the previous financial year.</li> <li>In FY22, the net assets of the company increased 8% to Rs. 993 crore as against Rs. 921 crore in the previous financial year.</li> <li>The total equity and liabilities of the company has also increased 8% to Rs. 993 crore as against Rs. 921 crore in the previous financial year.</li> <li>In FY22, the net cash used in operating activities of the company was Rs. 180 crore as against Rs. 121 crore in the previous financial year.</li> <li>The net cash used in investing activities of the company was Rs. 57 crore as against Rs. 66 crore in the previous financial year.</li> <li>The net cash generated from financial activities of the company was Rs. 231 crore as against Rs. 188 crore in the previous financial year.</li> <li>This shows that Bira's operational losses were compensated by raising funds from equity.</li> </ul> Incorporated in 2012, B9 Beverages Private Limited is engaged in trading and manufacturing of alcoholic beverages. In 2015, the company changed its name from Divya Jyoti Coaching Institute Private Limited to B9 Beverages Private Limited. The Company has its registered office at Connaught Place in New Delhi. <a href="https://unlistedzone.com/storage/knowledge-logo/Bira91-Standalone-Financials_March-2022.zip">Bira91 FY23 Results</a>
<p>“This high-growth unlisted share gained over 200 per cent; witnesses huge demand from investors! – Dalal Street Investment Journal – 7 Nov, 2022. The stock is quoting around Rs 3200-3300 for small lots i.e., 100 shares, meanwhile, for a lot size of 1000 shares it is quoting around Rs 3000 apiece.”</p> <div class="tatsu-column-pad-wrap"> <div class="tatsu-column-pad"> <div class="tatsu-animated-link tatsu-animated-link-style4 tatsu-HJ8Sw4OTnt tatsu-module tatsu-animated-link-align-none "><strong><a class="tatsu-animated-link-inner " href="https://www.dsij.in/dsijarticledetail/this-high-growth-unlisted-share-gained-over-200-per-cent-witnesses-huge-demand-from-investors-27198-1" target="_blank" rel="noopener" aria-label="Read Full Article Here"><span class="tatsu-animated-link-text">Read Full Article Here</span></a></strong></div> </div> </div>
<strong>1.</strong> In the second quarter, the saleable production up 11%YoY on account of completion of debottle-necking activity in blast furnace -3 in 1Q FY23. <strong>2.</strong> Half yearly saleable production increased by 2%YoY despite decrease in hot metal due to improvement in yield. <strong>3.</strong> ESL Margins have decreased amidst softening of steel prices post imposition of export duties by GOI and higher Coking coal prices. <strong>4.</strong> The margins have reduced from $70 dollar per ton to $19 dollars per ton due to reason mentioned at point number 3. ( Reduction of 72% in Margins) <img class="size-full wp-image-25105 aligncenter" src="https://unlistedzone.com/storage/knowledge-logo/Vedantu-Results.png" alt="" width="595" height="277" /> <strong>5.</strong> ~2500 Crores CAPEX is planned for ESL to increase the production capacity from 1.5 to 3 MTPA hot metal. Out of this, ~ 400 CAPEX has been done. <strong>6.</strong> Total debt on ESL as of 30.09.2022 is Rs. 2106 Crores after subtracting cash from it. <strong>7.</strong> Total revenue generated in the H1FY23 is ~3400 Crores which is up from ~2600 Crores in H1FY22. <strong>8.</strong> But due to margin pressure, the EBITDA has gone down from 295 Crores in H1FY22 to just 82 Crores in H1FY22. ( Reduction of 72% in Margins ).
<p><strong>HDB Financials Unlisted Shares Results</strong> <br /><br /><strong>1.</strong> For the quarter that ended September 30, 2022, HDB Financial's net revenue was at 2~200 crore as against ~1900 crore for the quarter that ended September 30, 2021, a growth of 14.9%. <br /><br /><strong>2.</strong> Profit after tax for the quarter that ended September 30, 2022, was ~470 crore compared to ~191 crores for the quarter that ended September 30, 2021. <br /><br /><strong>3.</strong> The total loan book of HDB Financials was 63,112 crores as on September 30, 2022. <br /><br /><strong>4.</strong> Gross NPA was at 4.88% of gross loans. <br /><br /><strong>5.</strong> As on September 30, 2022, the total Capital Adequacy Ratio was at 20.8% with Tier-I CAR at 16.0%. <br /><br /><strong>6.</strong> As on September 30, 2022, HDB Financials had 1,407 branches across 1,009 cities/towns. <br /><br /><strong>7.</strong> Considering that HDB Financial Unlisted Share is currently trading at 620 per share on the unlisted market, the P/B is 4.69x, which is a fair price. <br /><br /><strong>HDFC Securities Unlisted Shares Results</strong> <br /><br /><strong>1.</strong> For the quarter that ended September 30, 2022, HDFC Securities' total revenue was at 468 crores, as against 489 crores for the quarter that ended September 30, 2021. There is a drop of 5% in revenue as compared to last year. <br /><br /><strong>2.</strong> Profit after tax for the quarter was at ~190 crores, as against 240 crores for the quarter that ended September 30, 2021. There is a drop of 20% in revenue as compared to last year. <br /><br /><strong>Conclusion</strong> <br /><br />In summary, we can say that while HDB Financial's results are strong, HDFC Securities' performance in the second quarter was disappointing.</p>
<h4><strong>Ques. Why have you decided to not go ahead with the IPO?</strong></h4> <p>I think there are a couple of factors first and foremost, I think the companies on a very different and rapidly evolving trajectory while our companies had tremendous amount of growth for these last few years and we've grown more than 50% consistently we believe that going ahead the focus of the company must be on growth as well as profitability and we believe that within the next 12 months as the nearest and EBITDA Breakeven might be a much better time for us to tap the capital markets. I think most importantly we're proud of the fact that we are Mr Aditya Puri as our chairman I think he has one of the keenest years and the keenest understandings of how things are and where things should be so our focus is on growth as well as profitability and we are fairly confident that within the next 12 to 15 months the company will get to ebitda break even at which point of time we can come to the markets with the proposition of a company that is not really just growing phenomenally in the sector but also one that is ebitda Break Even.</p> <h4><strong>Ques. Do You have a requisite capital to grow in future?</strong></h4> <p>The capital buffer that we have in the company that was reportedly taken by the company around 300 million dollars from Goldman Sachs so there's a clarification yes 300 million dollars did come from Goldman size but it's a combination of 200 million dollars of straight debt and 100 million dollars of preference convertible Equity or a preference loan as we would call that right. So yes we have already received a cash infusion within the company and with the proposed rights issue that the company is going to undertake we will have enough and more Capital buffer to ensure that we are well set on our path and this trajectory of growth with profitability will definitely be seen the number performance very soon.</p> <h4><strong>Ques. How is business because you know a lot of Diagnostics talks have also been suffering because the COVID Tailwind is gone?</strong></h4> <p>So look I think it's very important to understand that as a group as API Holdings our business involves multiple things predominantly a large part of our Revenue comes from the sale of products which is either medicines or OTC products or devices a part a fair part of our Revenue also comes from Services which includes Diagnostics consultations and so on and so forth. Now as part of the overall Revenue mix if you look at the business as a whole FY22 vis-a-vis FY21 we've grown our net revenue and what I mean by net revenues is revenue recognised on the books of the company i.e. Net of taxes the point I'm trying to make is that our business is very resilient there are certain Pockets which will grow for example like you said at the time of COVID your testing will grow up but at that time the consumption of let's say acute medicines comes down in normal times let's say the consumption of acute medicine goes up your regular Wellness test goes up and testing comes down so our business is fairly resilient and has a wide portfolio of Revenue which ensures on the whole on aggregate the business continues to grow right.</p> <h4><strong>Ques. When you look at the results or what the other players have been saying from a Dr. Lal to SRL all of them the business and margins are going down?</strong></h4> <p>We are trying to compare the revenue of a segment of what we do yeah the pharmacy piece and overall right because as API Holdings we are a company that is involved predominantly across sale of medicines and provision of services right so I think it would be unfair to pick up part of our business and compare it to somebody else's business versus the right way to visualize a business is a combination of sale of medicines and services and on the whole we are growing more north of 50 percent year on year and the benefit of that is like I said I mean otherwise to take your cross selling and otherwise what should have happened is in the year of COVID we should have grown to 200 and the next day we've grown 30% and the next 20% because inherently the business has several modes and several advantages and in a lot of ways several Hedges also that some business will grow faster somebody will grow slower but on a aggregate basis we are still growing at a extremely rapid Pace right so I think the right proxy is to look at how is outpatient Healthcare growing and outpatient Healthcare has been growing 12 to 15% every year versus our growth for the past three years consistently has been 50%.</p> <h4><strong>Ques. Now the other thing I want to ask you the competition is rising the COVID may not be there which you're saying you're not worried about but competition is rising you've got TATA 1 mg I think all of us have seen those ads for 100 rupee tests right we're talking about disruption prices Flipkart has Grand plans we know Reliance has done what it has done via acquisition networks, Amazon wants to be in the diagnostic place. You said Pharmeasy wants to be in healthcare the fact is you will be the least capitalised out of all the names that have thrown at you how are you going to manage the competition?</strong></h4> <p>Look I think our inherent focus is our consumers internet focus is our business and what we can do to serve these consumers extremely profitably and how we can continue to grow in our market right. I think the beauty of it is the entire Healthcare Market is an exceptionally large Market. I always look at the advice of Mr Puri where he says that there is room not just for HDFC bank but then there is the ICICI Bank and then there is Kotak Bank and there is Bajaj finance and there is SBI and there is so many more right at last count there are 100 plus large companies which have a balancing north of billion dollars if I'm not wrong in their financial services space so there is room for so many and more right. I don't think we are living in a world where there's going to be one player who's going to take everything I think our strategy remains are consumers our retailers our partners our doctors and how we can provide the best of outpatient Healthcare to them in a single platform right and I think there is room for enough and more people to continue to come and not just survive but Thrive. This cross-selling was I mean idea of Aditya Puri, he’s known to provide everything that we need to give to the consumers at one place and he keeps on reemphasising that the focus of our platform is to provide everything in outpatient Health Care holistic health care and not just more importantly in urban areas but in semi-urban and Rural India also right I'm very proud to say that through our network of thyrocare we have a presence in 280 districts of India so 70% of a country's population can get access to a diagnostic test request it, get their sample drawn, get the sample flown into the laboratory habit process and get a result in under 24 hours or that our platform can now deliver medicines in every single habitable zip code of India right.</p> <h4><strong>Ques. What is your market share?</strong></h4> <p>I think it's you know it's almost like beauty is in the eyes of the beholder somebody can look at the market share as part of the digital ecosystem, somebody can look at it as part of just the pharmacy ecosystem, we would prefer to look at our market share as a part of the overall outpatient Healthcare ecosystem right because we straddle across outpatient Healthcare in information consultation Diagnostics and treatment today. The outpatient Healthcare Market is at least 60 billion dollars plus right so we are still a small insignificant less than two percent of the overall market right and there is so much of Headroom for us to continue to grow now so are you where are you in the pecking order of all of the big names that we talk about when it comes to outpatient care from the organized space so again I think there are like I said very different ways to evaluate market size because in terms of Diagnostics obviously, we have Dr lals, Metropolis who are significantly large in terms of market cap and revenues, and we are significantly larger in terms of the samples that we do and the number ofprocesses that we do, I think there are other companies that are doing a very good job in terms of retail pharmacies right, which we don't have there are some companies are very good in distribution right so I don't think it's fair to do apples to apple comparison because what we are doing is are significantly I would say integrated horizontal outpatient Healthcare platform which is giving holistic care and a lot of these platforms are doing a great job in their respective verticals right so unfair to compare us with them.</p> <h4><strong>Ques. Do you mean to suggest that you won't engage in the price battle that began these 100 rupee tests when you say it's not apples, it's apples and oranges?</strong></h4> <p>Look I think thyrocare has always championed the cause of being one of the most affordable diagnosis B2B labs in India right so I think the prices at which thyrocare does its test and the prices that it offers to its partners and through them to the consumers are already very competitive right so I think that the way we are just around 100 rupees it's yes it's in that zip code it's doing very well and at that price all I can say is that you know the numbers of thyrocare are there for everybody to say it's already very profitable right so we believe that at an affordable price at large volumes like the way our backend does we're able to create a platform that's extremely robust and profitable and growing extremely well.</p> <h4><strong>Ques. You know you have Mr Vidya puri's advice all the time with you did you consider more Acquisitions at one time you were on a serious shopping spree and now you want to sit on it?</strong></h4> <p>I think there is a time to acquire, I think there's a time to consolidate, all of our Acquisitions were done with an intent of building our platform score capabilities right and we said that even when we were chatting last year Diagnostics was one of the missing pieces of our core capability right which we would have taken a very long period of time to build out which we did right but I think we're now extremely well set and like I said everything in outpatient Healthcare information consultation Diagnostics and treatment we now have a very robust very large platform across the board and we hope that now our job much more is on integrating this even more and more closer and giving that as a single offering to the consumer versus now figuring out about a new offering at this point of time yeah because you know at the end of the day a patient would have a prescription right and whatever the doctor's instructions were on the app so you already have them and that's the cross-selling. So we want we want there to be a single place where you can come and say okay I want a consultation with the doctor my medical records to be stored, I can get a diagnostic test, I need a OTC product, I can get my medicines, I can get my refills, I get my reminders, all of it right and that is the focus and Genesis of it right it's almost like in HDFC Bank your one relationship manager will take care of everything for you right we want to be that partner for holistic healthcare for you it's a good line yeah.</p> <h4><strong>Ques. You withdraw the DRHP until you see profitability what can we expect have you started using your own cash ?</strong></h4> <p>I still think we have a pretty Healthy Growth and marketing budget but I think the company's Focus always I mean even when we had filed the DRHP if you look at our DRHP we had said that we are contribution margin positive yeah which means on every order or at an operational level we were making money yeah the focus was how fast can you scale those orders so that the profit we make from those orders is enough to take care of the cost we've reprioritized the business to focus on orders that are more and more profitable or services that are more and more profitable all activities that are more and more profitable and therefore we believe that going down the same path that we had laid down in the time of IPO we're just accelerating that and therefore we'll get to break even within 12 months so I think what you can expect from us over the next 12 months is the company that continues to have a significant focus on growth.</p> <h4><strong>Ques. Are founders selling Shares?</strong></h4> <p>We are not shutting down, we are not going to reduce our growth, exactly right I think I've heard but I want everything from the fact that you know Founders are running away or Founders are selling shares or Founders are going away I heard you're selling thyroid care also yeah so none of that is true. The founders have not sold one single share from the time we file the DRHP and we don't intend to sell any shares as a matter of fact we are considering putting some of our own money. There's another rumour in fact certain Publications printed that the founders removed close to 48 million dollars or the Senior Management got 48 million dollars from the company as a bonus I just want to clarify that the founders and Senior Management got that bonus linked to Performance initiatives that were agreed years in advance number one. Number two, all the money that the founders and Senior Management got every single rupee was reinvested back into the company so it wasn't like we got 50 million dollars and took home 50 million dollars, we got 50 million dollars reinvested the whole 50 million dollars in fact while we were doing this some of our team members said even we want to invest so our other team members invested another 10 million dollars so on a net net basis the Senior Management got 48 million dollars and invested 60 million dollars back into the company. We are considering infusing some of our own money even today even right now as a part of our rights issue because we are extremely confident about what we are doing.</p> <h4>Watch Full Interview Here:</h4> <p><iframe title="YouTube video player" src="https://www.youtube.com/embed/-UrG7P-lOYI" width="300" height="215" frameborder="0" allowfullscreen="allowfullscreen"><span data-mce-type="bookmark" style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" class="mce_SELRES_start"></span><span data-mce-type="bookmark" style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" class="mce_SELRES_start"></span></iframe> <br /><br />Credits: <a href="https://www.youtube.com/c/ETNow">ETNow</a></p>
<div class="page" title="Page 1"> <div class="section"> <div class="layoutArea"> <div class="column"> <strong>1.</strong> The GMV grew by 131% YoY and the top-line at Rs 540 Crores is up by 80% YoY. <strong>2.</strong> Mobikwik has achieved this phenomenal growth with a cash burn of only Rs 72 Crores, all of which was related to the first half as we turned EBITDA positive in the second half of the financial year 2021-22 <strong>3.</strong> As per management, the first 5 months of FY23 have seen as many credit disbursals as they did in the whole of FY22 and with a further decline in credit costs. <strong>4.</strong> Revenue is up from 302 Crores in FY21 to 543 Crores in FY22. <strong>5.</strong> Total expenses have gone up from 404 Crores in FY21 to 652 Crores in FY22. <strong>6.</strong> Mobikwik is still EBITDA negative with an EBITDA loss of 109 Crores in FY22. <strong>7.</strong> PAT loss is ~126 Crores in FY22. <strong>8.</strong> Cash flow from operations is still negative. That is ~320 Crores cash outflows from operations. <strong>9.</strong> Mobikwik services at a glance. <strong>10.</strong> Mcap = 5.71 *500 = 2900 Crores, a massive drop in valuation from ~$1 Billion dollar last year to almost 50% down now. <img class="wp-image-25068 aligncenter" src="https://unlistedzone.com/storage/knowledge-logo/Mobikwik.png" alt="" width="590" height="368" /> </div> </div> <div class="layoutArea"> <div class="column"> <strong>11.</strong> In accordance with the Employee Stock Option Scheme, Mobikwik has granted 7,14,493 fully paid-up equity shares worth Rs. 2 each to workers who exercised their vested options during the period under review. </div> </div> </div> </div> <div class="page" title="Page 2"> <div class="section"> <div class="layoutArea"> <div class="column"> Due to Covid-19 and the recent, Russia and Ukraine war </div> </div> <div class="layoutArea"> <div class="column"> This is the reason why the Private Equity market in India has raised a lot of money from investors in China, the US, Japan, Singapore, etc. </div> </div> </div> </div>
Fincare Business Services Limited has announced its annual report for the financial year ended March 31, 2022. As per the annual report, in FY22, the gross revenue of the company increased 18%, to Rs. 1707 crore as against Rs. 1448 crore in the previous financial year. The total expenses of the company increased 29%, to Rs. 1752 crore as against Rs. 1355 crore in the previous financial year. The company suffered a loss in FY22. In FY22, the Loss Before Tax of the company was Rs. (44) crore as against the Profit Before Tax of 92 crore in the previous financial year. In the financial year ended March 3, 2022, the net loss of the company was Rs. 29 crore as against net profit of Rs. 70 crore in the previous financial year. The EPS, diluted and basic, stood at Rs. 0.73 per equity share. The board of directors of the company didn't recommend any dividend for the financial year ended March 31, 2022. The total assets of the company reported an increase of 30%, Rs. 11049 crore as against Rs. 8485 crore. The equity and liabilities also stood at the same amount of Rs.11049 crore as against Rs. 8485 crore in the previous financial year. The net cash flow used in operating activities was Rs.(1383) crore as against Rs. (27) crore in the previous financial year and the net cash flow used in investing activities was Rs. (27) crore as against Rs. (2) crore in the previous financial year. The net cash flow generated from financial activities was Rs. 1436 crore as against Rs. 57 crore in the previous financial year. The net cash flow generated for FY22 was Rs. 25 crore as against Rs. 27 crore in the previous financial year. For the financial year ended March 31, 2022, the total investment of the company increased to Rs. 2118 crore as against Rs. 1317 crore in the previous financial year. Fincare Business Services Limited (formerly known as Fincare Business Services Private Limited) is a Non-Banking Financial Company. The Company was incorporated on 1 August 2014. The Company has converted itself from a private limited company to a public limited company with effect from 23 November 2016. The Company was incorporated primarily as a private company under the Companies Act,1956, to manage the capital requirement in associate companies and also provides the financial management and consultancy services. The Company has converted into a non-deposit accepting Non- Banking Financial Company - Core Investment Company (NBFC - CIC) with the Reserve Bank of India with effect from 2 February 2017.
Lotte India Corporation Limited has announced its annual report for the financial year ended March 31, 2022. The company witnessed rapid growth in its sales and gross revenue. However, due to high expenses, the profit of the company decreased significantly. For FY22, the gross income of the company increased 15%, to Rs. 458 crore as against Rs. 397 crore in the previous financial year. The total expenses of the company increased 19%, to Rs. 457 crore against Rs. 385 crore in the previous financial year. The PBT of the company witnessed a massive drop of 93%, to Rs. 90 lacs compared to Rs. 12 crore in the previous financial year. The net profit of the company increased 15%, to Rs. 11 crore as against Rs. 10 crore in the previous financial year. The basis earning per share of the company was Rs. 10.59 compared to Rs. 9.25 in FY21. The total assets of the company was Rs. 706 crore as against Rs. 710 crore in the previous financial year. The equity and liabilities of the company stood at Rs. 706 crore as against Rs. 710 crore. For FY22, the cash flow from operating activities of the company was Rs. 44 crore as against Rs. 54 crore in the previous financial year. The cash outflow from investing activities was Rs. 1 crore as against Rs. (30) crore in FY21. The net cash outflow from financial activities stood at Rs. (55) crore as against Rs. (36) crore in previous financial year. Net cash and cash equivalents decreased in FY22 was (6) crore as against Rs. (5) crore in FY21. Lotte India Corporation Limited is engaged in the business of manufacturing and marketing of confectionery products. It is the subsidiary of Lotte Confectionery Company Limited, South Korea, which is one of the leading manufacturers of confectionery products. The Company has three manufacturing plants in India and manufactures/ distributes a wide range of confectionery products including Chocopie, Coffy Bite, Lacto King, Frutopie, Caramilk, Coconut Punch and Spout Gums.
Rydak Syndicate Limited has announced its annual report for the financial year ended March 31, 2022. As per the annual report, the gross revenue of the company increased by 14%, to Rs. 147 crore, as against Rs. 129 crore in the previous financial year. During the financial year ended March 31, 2022, the total expenses increased 8%, to Rs. 122 crore as against Rs. 114 crore in FY21. The company has reported a massive increase in its PBT compared to the previous financial year. For FY22, the PBT of the company increased 66%, to Rs. 24 crore, compared to Rs. 15 crore for the previous financial year. The net profit for FY22 increased 57%, to Rs. 22 crore, as against Rs. 15 crore in the previous financial year. The total assets of the company increased by 10%, to Rs. 111 crore as against Rs. 101 crore in FY21. The total equity and liabilities of the company also increased by 10%, to Rs. 111 crore, compared to Rs. 101 crore in the previous financial year. For FY22, the net cash flow generated from operating activities was Rs. 24 compared to Rs. 21 crore in the previous financial year. During FY22, the net cash used in investing activities stood at Rs. 6 crore, compared to Rs. 8 crore in FY21. Net cash used in financial activities was Rs. 9 crore as against Rs. 13 crore in the previous financial year. The net increase in cash and cash equivalents for FY22 was Rs. 8 crore compared to Rs. ( 0.0040) crore in FY22. Rydak Syndicate Limited is a company incorporated under the Companies Act, 2013. The company’s shares are listed on the Calcutta Stock Exchange. The company is involved in harvesting, manufacturing, and selling of tea business. The company has also commenced operations commercially as a Tea Tourism operation in Dooars Region in the name of Baradighi –The Bungalow by converting one of its heritage Bungalows into a commercial property.
Elcid Investment Limited has announced its annual report for the financial year ended March 31, 2022. As per the report, in FY22, the total revenue of the company increased 25%, to Rs. 134 crore as against Rs. 107 crore in the previous financial year. In FY22, the total expenses of the company have also increased 206%, to Rs. 4 crore compared to Rs. 1 crore in the previous financial year. The PBT of the company has reported an increase of 23%, to Rs. 131 crore compared to Rs 106 crore in FY21. The net profit of the company has increased 23%, to Rs. 100 crore as against Rs. 81 crore in the previous financial year. The EPS, basic and diluted, of the company also increased to Rs. 5,001.94, up by 23% as against Rs. 4,052.46 in the previous financial year. The directors of the company recommended the final dividend of Rs. 15 pet equity shares for the financial year ended March 31, 2022. During the fiscal year that concluded on March 31, 2022, the ELCID had investments of Rs. 9164 Cr. According to their share capital, they have 2,000,00 outstanding shares. Therefore, if you divide this investment by the number of shares, the per-share value of ELCID unlisted share is Rs.4,80,000, and ELCID's delisting offer price was Rs. 1,62,000 and the same was rejected by investors as it was very low. The net cash flow from operating activities of the company was Rs. 61 crore as against Rs. 14 crore in the previous financial year and the net cash flow from investing activities was Rs. -68 crore compared to Rs. -11 crore in the previous financial year while the net cash flow from financial activities stood at Rs. -29 lakhs for FY22 which is the same as against the previous financial year. The net cash and cash equivalents for the financial year ended March 31, 2022 stood at Rs. 1 crore as against Rs. 8 crore in the previous financial year. In FY22, The total investment value of the company increased to Rs. 13159 crore as against Rs.10830 crore in the previous financial year. Elcid Investments Limited is a non-banking financial Company (NBFC) registered with the Reserve Bank of India (RBI) under the category of investment Company. The Company's activities primarily consist of investing in listed and unlisted equity shares, debt instruments of companies and in mutual funds.
Indicative prices, company research and your enquiries — in your pocket. Get price notes on the names you follow and reach our team from anywhere.
